Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The objective of this study was to validate vitamin D insufficiency as a CIPN risk factor.

Who Took Part

PubMed tags the participants as women only.

The researchers used data and samples from the prospective phase III SWOG S0221 (ClinicalTrials.gov identifier: NCT00070564) trial that compared paclitaxel-containing chemotherapy regimens for early-stage breast cancer.

The researchers quantified pretreatment 25-hydroxy-vitamin D in banked serum samples using a liquid chromatography-tandem mass spectrometry targeted assay.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The researchers also tested the direct effect of vitamin D deficiency on mechanical hypersensitivity in mice randomized to a regular or vitamin D-deficient diet.

What Was Measured

Topics PubMed links to this paper include Mice, Paclitaxel, Peripheral Nervous System Diseases, Breast Neoplasms, Vitamin D, Risk Factors and Vitamin D Deficiency.

Author keywords: chemotherapy-induced peripheral neuropathy, predictive biomarker and racial disparity.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Journal of the National Comprehensive Cancer Network : JNCCN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.